A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration by Schürch, Christian M. et al.
Schürch et al. 
	 1 
A Review on Tumor Heterogeneity and Evolution in Multiple 
Myeloma: Pathological, Radiological, Molecular Genetic, and 
Clinical Integration  
 
Christian M. Schürch1, Leo Rasche2, Leonie Frauenfeld3, Niels Weinhold4, Falko Fend3 
 
1 Department of Microbiology and Immunology, Stanford University School of Medicine, 
Stanford, CA, USA 
2 Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany 
3 Institute of Pathology and Neuropathology and Comprehensive Cancer Center, University 
Hospital Tübingen, Tübingen, Germany 
4 Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany 
 
Correspondence 
Falko Fend, Institute of Pathology and Neuropathology, University Hospital Tübingen, 
Liebermeisterstrasse 8, 72076 Tübingen, Germany;  





Christian M. Schürch: 0000-0002-1792-1768  
Leo Rasche: 0000-0002-9536-9649 
Falko Fend: 0000-0002-5496-293X 
 
Word count (excluding abstract, references, legends): 4277 
 
Keywords 
Multiple myeloma; personalized medicine; plasma cell neoplasms; review; tumor evolution; 
tumor heterogeneity  
Schürch et al. 
	 2 
Abstract 
Recent research has dramatically advanced our understanding of the genetic basis of multiple 
myeloma (MM). MM displays enormous inter- and intratumoral heterogeneity, and underlies a 
clonal evolutionary process driven and shaped by diverse factors such as clonal competition, 
tumor microenvironment, host immunity, and therapy. 
Two main cytogenetic groups are distinguished: MM with recurrent translocations 
involving the immunoglobulin heavy chain locus, and MM with hyperdiploidy involving the 
odd chromosomes. The disease virtually always starts with a preneoplastic prodromal phase – 
monoclonal gammopathy of undetermined significance – that variably progresses to 
symptomatic MM within a few months or many years. Tumor heterogeneity and its evolution 
in space and time have important consequences for the clinical management and outcome of 
MM patients. At diagnosis, spatial intratumoral heterogeneity poses a challenge for 
classification and risk stratification. During maintenance therapy, clonal evolution may 
complicate disease monitoring and promote drug resistance. Upon progression or 
transformation, identifying the dominant disease-driving neoplastic clones and elucidating their 
properties are key to tailor personalized therapy.  
In this review, we discuss tumor heterogeneity and clonal evolution in MM, integrating 
pathological, radiological, molecular genetic, and clinical data. Current and prospective 
classification schemes and prognostic parameters, incorporating new genetic and proteomic 
discoveries and advances in imaging, are highlighted. In addition, the roles of the tumor 
microenvironment, host immunity, and resistance mutations, and their effects on therapy, are 
discussed. 
An improved understanding of high-risk disease, tumor heterogeneity, and clonal 
evolution will guide future therapies and may ultimately lead towards a cure for MM. 
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Introduction 
Plasma cell neoplasms (PCNs) arise from terminally differentiated antibody-producing B cells 
and evolve through a chain of genetic events from the indolent, pre-malignant disorder 
monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) 
and its end-stage variants. MM is the second most common hematological malignancy, 
affecting >90,000 individuals in the United States and representing 1.6% of all cancers [1]. The 
clinical behavior of MM and other advanced PCNs is very heterogeneous, with survival rates 
ranging from months to decades [2]. This heterogeneity can be attributed to tumor genetics and 
epigenetics, as well as a range of extrinsic factors including the tumor microenvironment 
(TME), disease stage, and host immune response [3-9]. The diagnosis and classification of 
PCNs is based on integration of clinical, serological, pathological, radiological, and molecular 
genetic findings. PCNs are categorized as precursor lesions, i.e. MGUS and smoldering MM 
(SMM); solitary plasmacytoma with osseous or extraosseous localization, standard-risk MM, 
and high-risk disease including advanced and relapsed/refractory (R/R) MM [10]. Furthermore, 
in the WHO classification, specific subtypes of PCNs are recognized based on their 
predominant clinical symptoms, such as AL amyloidosis; their association with specific 
syndromes, such as POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal 
gammopathy and Skin changes); or their anatomic location, as for extramedullary 
plasmacytoma (EMP) and plasma cell leukemia (PCL).  
New treatment strategies including proteasome-targeting drugs, monoclonal antibodies 
(mAbs), immunomodulators and autologous hematopoietic stem cell transplantation (auto-
transplant) have induced long-term remissions and improved the outcomes of many MM 
patients. On average, fit elderly patients have a median overall survival (OS) of 5 years, and 
OS in younger patients receiving auto-transplant approaches 10 years [11]. However, for the 
20-30% of MM patients with high-risk disease, even the most intensive therapies have not 
resulted in satisfactory outcomes [10, 12]. In these patients, tumor heterogeneity and clonal 
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evolution of MM under therapy favor the emergence of resistant clones that lose their 
dependence on the bone marrow (BM) microenvironment, ultimately relapsing as end-stage 
EMD or PCL [10]. Therefore, identifying high-risk patients and treating them accordingly is 
key to improve global outcomes in MM. This can be achieved by correct interpretation and 
integration of diagnostic findings from multiple clinical disciplines, including pathology, 
radiology and clinical genomics.  
Recent sequencing efforts have shed light on the mutational landscape of PCNs and 
have unraveled a complex picture of initiation, evolution, and progression of these diseases, 
leading to inter- and intratumoral heterogeneity (Figure 1). Combining advanced medical 
imaging modalities with targeted biopsies and genetic investigation has provided insights into 
spatial intratumoral heterogeneity and regional genetic variation, uncovering the primary 
existence – or drug-induced emergence – of high-risk, disease-driving subclones that determine 
prognosis. These findings have raised new challenges for PCNs with regard to initial diagnosis 
and classification, as well as for follow-up protocols under therapy [10], and raise the following 
important questions: (1) What practical impact have pathological and genetic heterogeneity and 
clonal evolution on the clinical management of patients with PCN? (2) What is the role of 
advanced imaging modalities, i.e. diffusion-weighted magnetic resonance imaging (DW-MRI) 
and 18fluoro-deoxyglucose positron emission tomography / computed tomography (FDG-
PET/CT) in routine PCN diagnosis and follow-up? (3) How does tumor heterogeneity as seen 
in these imaging modalities, such as large focal lesions (FLs) or EMD, influence downstream 
diagnostic procedures including guided lesion biopsies and extended sequencing? (4) What is 
the best way to integrate pathological, radiological and genetic findings (e.g. from multiple 
heterogeneous lesions), and what is their impact on prognosis and prediction of therapy 
response?  
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In this review, we will address these questions from a multidisciplinary point of view, 
integrating current knowledge on the biology, pathology, genetics, imaging, and clinical 
features of PCNs with a special focus on the impact of tumor heterogeneity. 
 
Heterogeneity at the pathological level 
According to the Revised 2017 WHO Classification of Tumors of Hematopoietic and 
Lymphoid Tissues, PCNs are subdivided into 5 categories: (1) non-IgM MGUS; (2) plasma cell 
myeloma/MM, (3) solitary plasmacytoma; (4) monoclonal immunoglobulin (Ig) deposition 
disease; and (5) PCNs with associated paraneoplastic syndrome [13]. Trephine BM biopsies 
and aspirates continue to be pivotal for a correct diagnosis of PCNs. BM aspirates are often 
helpful to assess cytological abnormalities, but can sometimes be negative for plasma cells due 
to the heterogeneous distribution in the BM. Sheets of malignant plasma cells displaying 
cellular and nuclear atypia including multinucleation and prominent nucleoli, in combination 
with positivity for CD138, light chain restriction, and aberrant expression of CD56 in 
immunohistochemistry (IHC), render the diagnosis of MM. However, early cases with low 
percentages of neoplastic plasma cells are more challenging, and a diagnosis of MM requires 
the integration of clinical features, especially the presence or absence of CRAB criteria 
(hyperCalcemia, Renal insufficiency, Anemia and Bone lesions) (Table 1). In these early 
stages, morphological findings such as the dissociation of groups of plasma cells from their 
usual perivascular BM niche or signs of active bone resorption can provide a hint at the 
diagnosis. Prominent nucleoli, intracytoplasmic and intranuclear immunoglobulin inclusions 
(Russell bodies, Dutcher bodies, respectively) and deposits in macrophages (Gaucher-like cells 
or crystalline inclusions, respectively) may point to malignancy but may also be found in 
reactive processes and are therefore not specific. In addition to their diagnostic utility, 
morphology and IHC deliver valuable information with regards to potential biological and 
molecular genetic mechanisms driving the PCN. For example, MM with lymphoplasmacytoid 
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morphology is frequently associated with t(11;14)(q13;q32) translocation, exhibits staining for 
cyclin D1 in IHC and is commonly CD20-positive, potentially even resulting in a misdiagnosis 
of mantle cell lymphoma [14, 15] (Figure 2). Strong and homogeneous nuclear cyclin D1 
positivity can be taken as a surrogate for the presence of a t(11;14) translocation, whereas more 
heterogeneous and weaker reactivity is observed mainly in cases with trisomy 11 [15]. In 
MGUS, cyclin D1 expression in plasma cells can confirm the presence of a clonal proliferation. 
Rare heavy chain isotypes are also associated with specific features; e.g. 20% of PCNs with 
lymphoplasmacytoid morphology are IgD-producing, whereas the rare IgM-producing MM 
shows conventional morphology and is CD20-negative, despite containing the t(11;14) 
translocation in >80% of cases [16-18]. Further cytomorphological features include mature, 
intermediate, immature and plasmablastic morphology, the latter associated with significantly 
worse prognosis and common MYC translocations, which usually represent a secondary genetic 
event in MM. Of note, plasmablasts and plasmablastic myeloma have been defined by different 
criteria cytologically (i.e., in the BM aspirate) and histologically (i.e. in the BM trephine biopsy) 
[18-20]. Cytologically, Greipp et al. defined plasmablasts as having a large central nucleus (>10 
µm diameter) or a large nucleolus and scant cytoplasm; for a diagnosis of plasmablastic 
myeloma, plasmablasts needed to constitute >2% of nucleated marrow cells in the aspirate. In 
contrast, Bartl et al. characterized plasmablastic myeloma as having a majority of cells with 
immunoblast-like features with prominent central nucleoli and rather scant cytoplasm in the 
BM trephine. Irrespective of these different diagnostic criteria, plasmablastic myeloma usually 
accounts for 5-15% of MM cases and shows aggressive behavior.  
The phenotype and phenotypic variability of malignant plasma cells is also exploited in 
flow cytometry, which is a mainstay in the diagnostic evaluation and especially minimal 
residual disease detection of MM. In addition, the antigen profile of clonal plasma cells has 
been used for prognostic purposes and for risk assessment in MGUS and SMM [21-25].  
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Another aspect of heterogeneity at the pathological level are solitary plasmacytomas, 
accounting for about 6-10% of all PCNs, which manifest either as solitary osteolytic lesion or 
as a tumoral proliferation in an extramedullary location, mostly mucosal sites in the head and 
neck region, less commonly in lymph nodes. Although extramedullary plasmacytomas (EMPs) 
by definition do not show BM involvement, sensitive techniques can detect clonal BM plasma 
cells in the majority of patients with EMP [26]. Furthermore, EMPs are very similar to MM 
both phenotypically and genetically, with the exception that EMPs are usually negative for the 
t(11;14) translocation and markers of advanced disease, such as MYC translocations or TP53 
alterations [27, 28]. Despite this close relationship to MM, EMPs shows a good prognosis with 
local radiotherapy alone, and only about 15% of patients progress to systemic disease. This 
underlines the importance of non-genetic factors for disease progression. From the practical 
point of view, separation of generally indolent EMPs from aggressive extramedullary disease 
is of great importance, and usually relies on the clinical circumstances and certain pathological 
features such as cellular maturity and the identification of markers of aggressive disease 
(Figure 2). 
MM focal lesions (FLs) are localized tumor cell accumulations that are present in the 
majority of MM patients at diagnosis and are detectable by advanced imaging modalities 
(Figure 3). FLs represent mutational hotspots consistent with the regional outgrowth of 
advanced tumor clones [29]. Detailed histopathological analyses on the cellular composition 
and spatial organization of MM FLs are largely lacking, mainly because of their frequently 
difficult localization and accessibility for radiological guided biopsy. Tissue from FLs can be 
obtained during surgery for pathological fractures, and preliminary studies on these FLs 
compared to matched random BM biopsies did not show significant differences in the 
proliferation rate of malignant plasma cells (L.R. and N.W., unpublished observations). 
However, systematic studies addressing the FLs’ tissue characteristics, including mapping their 
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immune tumor microenvironment, have not yet been performed, and there are surprisingly 
limited data on osteolytic lesions. 
In summary, MM shows significant heterogeneity at the pathological level, and the 
pathologist can use morphological cues and IHC to guide downstream analyses, such as genetic 
testing. Future pathology studies in MM should focus on, and describe in detail, the spatial 
organization of FLs. 
 
Heterogeneity at the molecular genetic level 
MM is characterized by extensive inter-patient heterogeneity [30]. Yet, it can be broadly 
categorized into two groups: those with Ig heavy chain gene translocations involving 
chromosome 14q32 (including, in descending order of frequency, t(11;14), t(4;14), t(14;16), 
t(14;20) and t(6;14)); and those with hyperdiploid genomes (i.e., trisomies of odd-numbered 
chromosomes with the exception of 1, 13 and 21). Additional gross chromosomal aberrations, 
such as deletions and amplifications, are often observed, leading to emergence of new sub-
clones and intratumoral heterogeneity. To better understand intratumoral heterogeneity, we 
recently sequenced several MM samples from the same patient, including iliac crest and 
radiology-guided FL biopsies. Spatial genomic heterogeneity at the chromosomal and 
mutational level, where somatic aberrations were present at one site but absent at another 
(private mutations), was observed in the majority of patients. On average, three unshared copy 
number aberrations (CNAs) between paired samples were found in these patients. These 
included spatial differences in commonly used prognostic markers such as del(17p), MYC 
translocations, and aberrations of chromosome 1. In contrast, initiating events such as t(11;14) 
and t(4;14) were uniformly shared among investigated regions, consistent with their role as 
early disease drivers. In addition, mutational analysis revealed that private mutations were 
found in 76% of newly diagnosed MM (NDMM) patients [29]. The non-homogeneous 
distribution of high-risk clones and potentially targetable driver mutations pose a significant 
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challenge for correct risk classification and effective therapy [29, 31, 32]. The prime, clinically 
relevant example of spatial heterogeneity discovered in this study was in a patient who had an 
ultra-high-risk clone in a biopsy from the lumbar spine that had a high-risk score according to 
gene expression profiling (GEP) data, a bi-allelic TP53 deletion and an aberration of 
chromosome 1p, all of which were absent in the iliac crest biopsy. In contrast, the iliac crest 
biopsy was GEP low-risk, had a hyperdiploid karyotype and a BRAFV600E mutation.  
 A recent investigation of 1273 NDMM patients yielded profound insight into the 
interplay of commonly mutated genes. Walker et al. found significant associations between 
certain translocations, oncogene or tumor suppressor gene mutations, chromosomal copy 
number changes, and hyperdiploidy. Examples of such events included t(11;14) in combination 
with mutations in CCND1 and IRF4; t(4;14) in combination with mutations in FGFR, DIS3 and 
PRKD2; and hyperdiploidy in combination with gain 11q, mutations in FAM46C and MYC 
rearrangements, amongst others [33]. Some of these mutations, such as those in CCND1 and 
FGFR, are probably the effect of aberrant somatic hypermutation targeting translocated genes. 
Furthermore, the authors observed a significant inverse correlation between the number of 
oncogenic driver mutations per sample and progression free as well as overall survival. In 
addition, this study found novel potentially targetable mutations in the epigenetic regulators 
IDH1 and IDH2, and identified associations between certain BRAF mutations and chromosomal 
translocations, i.e. t(14;16) and BRAFD594N, and t(4;14) and BRAFV600E [33]. The latter finding 
is clinically relevant since BRAF inhibitors are selective for BRAFV600E and should not be used 
in patients with BRAFD594N or RAS mutations [31, 34, 35].  
 
Heterogeneity at the radiological level 
MM intra- and intertumoral heterogeneity are clearly reflected at the radiological level. While 
some patients present with a diffuse plasma cell BM infiltration only, up to 75% of patients 
show FLs, localized accumulations of tumor cells in the skeletal system (Figure 3). Number, 
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size, location in the skeleton (axial vs. appendicular), type (intra-, para- or extramedullary), and 
metabolism of FLs differ between patients, dramatically increasing the extent of inter-patient 
heterogeneity in MM. The two main imaging techniques used for disease detection are 18F-
fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and 
diffusion weighted magnetic resonance imaging (DW-MRI). While FDG-PET/CT is based on 
the quantification of increased glucose uptake by tumor cells, in DW-MRI cellularity is 
measured by quantifying the diffusion of water molecules and the microcirculation of blood in 
the capillary network [36, 37]. FDG-PET/CT and DW-MRI have comparable diagnostic 
accuracy, and DW-MRI has the advantage of not exposing the patient to ionizing radiation [38-
40]. 
Clinically, the focus has been on the number and type of FLs. Both, EMD and more 
than 3 FLs in FDG-PET/CT negatively impact outcome [41-46]. Another variable that seems 
to impact prognosis is the location of FLs: Abe et al. recently showed that MM patients with 
multiple FLs in the appendicular skeleton suffered from poor outcome [47]. Combining whole-
body functional imaging and data from multi-region sequencing, we identified the size of FLs 
as an important variable [29, 46]. We demonstrated that spatial differences were mainly seen 
in patients with large (>2.5 cm) FLs, suggesting that clinical imaging can be used to identify 
patients with extensive intratumoral heterogeneity. Indeed, using the size of FLs as a surrogate 
marker for the level of intratumoral heterogeneity, we showed that the presence of multiple 
large FLs was an independent adverse prognostic factor in MM [46]. Accounting for the size 
of FLs, more than 3 FLs in FDG-PET/CT were not prognostically relevant anymore.  
We have shown that highly advanced clones can be restricted to an FL [29]. Since response to 
treatment could be different at that location compared to other sites in the BM, the question 
becomes whether iliac crest sampling is sufficient for disease monitoring during treatment. We 
and others have recently tested the value of imaging as an alternative method for detection of 
minimal residual disease (MRD) [25, 48]. Using the two functional methods, DW-MRI and 
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FDG-PET/CT, we showed that one fourth of NDMM patients still had residual FLs when they 
achieved complete remission (CR). Combining flow cytometry for MRD detection and the two 
imaging methods, we demonstrated that less than 10% of MRD-negative NDMM patients in 
CR still presented with residual FLs. In contrast, ~50% of heavily pretreated patients who 
achieved MRD-negative CR during salvage therapy presented with FLs, illustrating the value 
of functional imaging in these patients [49]. Last but not least, the spleen signal on DW-MRI 
also provides prognostic information, in that patients lacking spleen signal usually show high 
tumor burden and poor prognosis, especially when suffering from high-risk disease [50]. 
 
Role of the BM microenvironment and host immunity in MM heterogeneity  
Recent evidence indicates that intratumoral heterogeneity can be influenced by clonal 
competition, clonal cooperativity, pH, oxygenation, and the BM microenvironment (BMME) 
[4-6, 9, 51, 52]. The role of the BMME in MM pathogenesis has been extensively reviewed 
[53-57]. The BM is a complex organ consisting of numerous highly specialized cell lineages 
that orchestrate blood production, immunity, and skeletal integrity over a lifetime of an 
organism. Because mature, long-lived plasma cells primarily reside in the BM, the BMME is 
key in the development and progression of MM (Figure 4) [54]. As an immunological organ 
by itself, the BM hosts a wide range of immature and mature innate and adaptive immune cell 
types [58]. To accommodate its high metabolic needs, the BM is also richly vascularized with 
different types of arterioles, transitional capillaries, and sinusoids [59]. Besides these cellular 
compartments, which also include mesenchymal cells such as BM stromal cells, adipocytes and 
osteolineage cells, the BMME consists of solid extracellular matrix components (such as 
collagenous bone) and a liquid milieu containing growth factors, cytokines and chemokines. 
Immune, stromal, osseous and endothelial cells all contribute to this milieu, which promotes 
survival, proliferation, and drug resistance of MM cells [56]. By secreting regulatory cytokines 
such as transforming growth factor (TGF)-β and interleukin (IL)-10, MM cells induce a local 
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and systemic immunosuppression that prevents host antitumoral immunity and contributes to 
an increased susceptibility to infections [60]. In addition, MM cells produce angiogenic factors 
such as vascular endothelial growth factor (VEGF), angiopoietin-1 and fibroblast growth factor 
(FGF), which contribute to the enhanced BM angiogenesis observed in MM patients [55, 61]. 
Interestingly, MM cells also produce exosomes that carry multiple angiogenic factors and 
directly promote endothelial cell growth [62]. Of note, Nakamura et al. recently demonstrated 
that IL-18, produced by multiple cell types in the BMME, drove the generation of MM-
supporting myeloid-derived suppressor cells (MDSCs) that negatively impacted antitumoral 
CD8+ T cell responses, and showed that high IL-18 levels in BM plasma were associated with 
poor outcome in MM patients [63]. Indeed, BM MDSCs were already reported earlier to play 
a pivotal role in MM pathogenesis [64]. In addition to cytokines and growth factors, MM cells 
express adhesion factors such as CD38 that allow them to adhere to BM endothelial and stromal 
cells. BM stromal cells in turn up-regulate the expression of IL-6 and other cytokines that 
activate osteoclasts (OCs) and drive MM cell proliferation [53]. Interestingly, a study by 
Frenquelli et al. showed that ROR2, a receptor for the non-canonical WNT pathway, is essential 
for MM cell interactions with the BMME, and that ROR2 inhibition led to MM cell detachment 
resulting in apoptosis [65]. OCs, bone resorbing cells that are formed as giant syncytia by the 
fusion of monocytes, are mainly responsible for the MM-specific bone lesions and the increased 
risk of fractures. OC numbers and activity are strongly enhanced in MM, and OCs directly 
protect MM cells from immune action by CD4+ and CD8+ T cells [66]. Numerous additional 
BMME cell types including osteoblasts, macrophages and plasmacytoid dendritic cells were 
shown to contribute to MM pathogenesis [67-69]. Many currently available MM therapies, 
including immunomodulators and bisphosphonates, exert their functions at least in part by 
affecting non-tumor cells in the BMME [56]. However, insights into the mechanisms by which 
the BMME supports or even promotes MM heterogeneity are almost completely lacking. An 
important factor for the establishment of intratumoral heterogeneity is the ability of MM cells 
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to mobilize into the bloodstream and re-enter the BM at different sites. The chemokine receptor 
CXCR4, a key mediator of hematopoietic stem cell retention in the BM, also plays a role in the 
interactions of MM cells with the BMME. Inhibiting CXCR4 with the drug plerixafor 
(AMD3100) disrupted these interactions, mobilized MM cells into the periphery and increased 
their sensitivity to multiple therapeutic agents [70]. 
In summary, the BMME and host immunity both are crucial factors in MM 
pathogenesis. Future studies should address how they contribute to MM genetic heterogeneity 
and why end-stage diseases such as EMD and PCL lose their dependence on 
microenvironmental survival signals. Answering these important questions will improve our 
understanding of MM in general and pave the way for future therapies. 
 
Current therapy and the impact of tumor heterogeneity 
Although molecular segmentation strategies have shown the extent of tumor heterogeneity in 
MM, the standard clinical approach is still more akin to “one size fits all”. Younger individuals 
and medically fit patients aged up to 75 years undergo induction therapy utilizing at least one 
of the so-called novel agents lenalidomide or bortezomib, followed by peripheral stem cell 
apheresis, high-dose melphalan therapy, auto-transplant, and lenalidomide maintenance 
therapy. In some centers, a second high-dose therapy with auto-transplant 2-6 months after the 
first transplant (“tandem”) is preferred over a single transplant. The standard dose of melphalan 
is 200 mg/m2; in elderly or frail patients the dose is frequently reduced to 140 mg/m2. 
Consolidation therapy after auto-transplant is another strategy to improve depth of response, 
and probably outcomes. The efficacy of these additional elements is still a matter of debate 
[71]. However, Total Therapies, which include multi-agent induction therapy, two auto-
transplants, consolidation, and intensified maintenance have produced the best reported 
outcomes so far with some patients even considered to be cured [72]. Treatment for transplant-
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ineligible patients typically consists of doublet or triplet drug regimens, which are frequently 
combined with daratumumab, an anti-CD38 monoclonal antibody [73, 74].  
Only few studies have investigated specific treatments for GEP-defined high- and low-
risk disease [75, 76]. Unfortunately, these studies were not successful and could neither support 
intensification in high-risk nor de-escalation in low-risk patients. In a study by Cavo et al., 
patients with high-risk disease, defined there as international staging system (ISS, Table 2) 
stage II+III, high-risk cytogenetics and failure to achieve CR, benefited from tandem transplant 
as compared to single transplant (median progression-free survival: 35 vs. 14 months). 
However, overall survival in the high-risk group was still clearly inferior when compared to 
standard-risk patients. These results suggest that double-transplant delays disease progression 
in high-risk patients but does not overcome high-risk disease per se [77]. In summary, current 
clinical practice usually does not take into account tumor heterogeneity, with a few exceptions, 
which are discussed below, and recapitulated in Table 3. 
Treatment with venetoclax, an oral BH3-mimetic, in patients harboring translocation 
t(11;14) is a good first example for individualized MM therapy utilizing the distinct 
susceptibility of this molecular subtype to BCL-2 inhibition. Tumor cells with t(11;14) show a 
more B cell-like phenotype and more likely express high levels of BCL-2 relative to BCL-XL 
and MCL-1. Evaluating single-agent venetoclax in R/R MM, the overall response rate was 21%, 
and most responses (86%) were seen in patients with t(11;14) translocation, with 27% of these 
patients achieving a very good partial response (VGPR) or better [78]. Combining venetoclax 
with bortezomib and dexamethasone the overall response rate was 67% in patients with R/R 
MM, and 42% of patients achieved a VGPR or better [79]. Response was not limited to cases 
with t(11;14), but best overall response rate was observed in patients with high BCL-2 
expression (94%). Notably, patients with bortezomib-sensitive disease were more likely to 
respond than those whose disease was refractory to prior bortezomib, suggesting that 
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venetoclax cannot fully overcome bortezomib resistance [80]. In summary, treatment with 
venetoclax in patients with t(11;14) represents the prime example for personalized MM therapy. 
However, venetoclax is not yet officially approved for the treatment of MM by the United States 
Food and Drug Administration (FDA), and it is not mentioned in the National Comprehensive 
Cancer Network (NCCN) guidelines for MM [81]. 
Another good example is the impact of proteasome inhibitors on t(4;14)-positive MM, 
a subgroup with dismal outcomes before the introduction of this class of drugs. At the 
University of Arkansas for Medical Sciences in Little Rock, Dr. Barlogie and team treated 
patients with several generations of Total Therapy encompassing multi-agent induction 
therapy, two auto-transplants, and intensified maintenance. Bortezomib was introduced in Total 
Therapy 3a in the induction, consolidation and maintenance phase of therapy. A survival benefit 
was mainly seen for patients with t(4;14), highlighting a favorable effect of proteasome 
inhibition particularly in this subgroup [12]. Avet-Loiseau et al. reported on 507 NDMM 
patients treated with bortezomib/dexamethasone induction followed by transplant and also 
observed significantly improved overall survival for t(4;14) positive cases [82]. In summary, 
proteasome inhibitors improve outcomes in patients with t(4;14). Bortezomib maintenance is 
one option recommended in the NCCN guidelines for MM [81]. 
The third example for personalized therapy is the use of vemurafenib and other BRAF 
and MEK inhibitors in BRAFV600E mutated MM [83-85]. Mutations at this location occur in 
>5% of NDMM and the frequency increases from baseline to relapse [83, 86]. Raab et al. and 
others have reported on patients achieving CR after BRAF targeted therapy in R/R MM, and a 
phase 2 trial (BIRMA trial, NCT02834364) is currently evaluating this concept in a larger 
number of patients [83]. However, although being the proof of concept for targeting actionable 
mutations, duration of response is often short and patients relapse with BRAFV600E negative 
clones [31]. Moreover, mutations in genes involved in the MAP kinase pathway are subclonal 
in the majority of patients [31, 87] and spatial genomic heterogeneity has been reported for 
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these potential targets [29]. Together, targeting mutations in MM may be an approach for R/R 
patients with limited therapeutic options. However, we recommend genomically characterizing 
these patients and discussing the results in the framework of a molecular tumor board. 
 
Conclusions  
Recent research has uncovered a striking amount of inter- and intratumoral 
heterogeneity in PCNs at all levels of investigation. Despite our increased understanding of 
PCNs and better therapies, which have resulted in an improved outlook for the majority of 
patients, spatially distributed genetic and biological heterogeneity with outgrowth of aggressive 
and therapy-resistant subclones still preclude long-term cure in most patients. The combination 
of advanced imaging modalities combined with targeted genetic investigation of FLs may lead 
to better risk estimation and early identification and targeting of aggressive subclones. Yet, how 
the ever more complex personalized MM medicine can be harmonized with increasing 
economic pressures and patient dignity is a challenge for the future. 
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Tables 
Table 1: WHO definition of MM 
Parameter Diagnostic criterion 
1. Clonal plasma cell neoplasm (clonality proven by IHC, IF or flow cytometry) 
Clonal BM plasma cells > 10% 
OR 
Plasmacytoma biopsy-proven  
AND 
2. Any one of the following myeloma-defining events 
Any one of the 
following criteria of 
end-organ damage  
(CRAB-criteria) 
HyperCalcemia (>0.25 mmol/L above normal or > 2.75 
mmol/L) 
Renal insufficiency (creatinine clearance <40 ml/min or serum 
creatinine > 177 μmol/L 
Anemia (hemoglobin > 20 g/L below normal, or < 100 g/L) 
Bone lesions (one or more osteolytic lesions on skeletal 
radiography, CT, or 18F-FDG-PET/CT 
OR 
Any one of the 
following biomarkers of 
malignancy 
• Clonal BM plasma cells ≥ 60% 
• Involved-to-uninvolved serum free light chain ratio ≥ 100 
(involved free light chain must be ≥ 100 mg/L) 
• >1 focal lesion on MRI (each ≥ 5mm in size) 
Adapted from [13, 88] 
 
Table 2: International Staging System (ISS) and Revised ISS (R-ISS) for MM 
Parameter ISS stage I R-ISS stage I 
 all of the following: all of the following: 
Serum albumin ≥ 35 g/L ≥ 35 g/L 
Serum β2-microglobulin < 3.5 mg/L < 3.5 mg/L 
Serum lactate dehydrogenase not considered normal 
Cytogenetics not considered non-high-risk: absence of 
t(4;14), t(14;16), del(17p) 
 
 ISS stage II R-ISS stage II 
ISS / R-ISS stage not ISS stage I or III not R-ISS stage I or III 
 
 ISS stage III R-ISS stage III 
Serum β2-microglobulin ≥ 5.5 mg/L ≥ 5.5 mg/L 
 AND 
Serum lactate dehydrogenase not considered elevated 
 OR 
Cytogenetics not considered high-risk: presence of 
t(4;14), t(14;16) or del(17p) 
Adapted from [2, 89] 
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Adapted in part from [1]. Abbreviations: ADAR1, adenosine deaminase acting on RNA 1; 
APOBEC, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like; BET, 
bromodomain and extra-terminal motif protein; BH3, BCL-2 homology domain 3; BM, bone 
marrow; BMME, BM microenvironment; CCND, Cyclin D; CDK, cyclin-dependent kinase; 
CCR1 C-C chemokine receptor 1; FGFR3, fibroblast growth factor receptor 3; MAF, V-Maf 
Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog; MAP, mitogen-activated 
protein kinase; MCL-1, myeloid cell leukemia-1; MMSET, multiple myeloma SET domain; 
MYC, V-Myc Avian Myelocytomatosis Viral Oncogene Homolog; PD-1, programmed cell 
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Figure legends 
Figure 1. Tumor heterogeneity in MM. At the highest genomic level, inter-
patient/intertumoral heterogeneity (top panel) can be viewed as patients having tumors with 
hyperdiploid genomes (~50%) or primary Ig heavy chain (IgH) translocations (~50%), with 
rare exceptions showing a combination of both. Moreover, there is a vast variability at the level 
of additional driver mutations between patients, as well as differences in the distribution of 
lesions and their histomorphological appearance, further contributing to intertumoral 
heterogeneity (not depicted). Intra-patient/intratumoral heterogeneity (bottom panel) can be 
described as the heterogeneous distribution of genetically distinct MM clones and subclones 
within a single patient. Intratumoral heterogeneity may complicate diagnostics and 
classification and represents a significant challenge for optimal personalized therapy. 
 
Figure 2. Heterogeneity at the pathological level. (A-E) Extramedullary solitary 
plasmacytoma of the upper airways shows an infiltration by mature plasma cells with absence 
of significant atypia. (A-B) Giemsa staining, 100x and 400x magnification, respectively. (C-E) 
IHC for (C) MUM-1/IRF-4, (D) kappa (highlighting the malignant clone), and (E) lambda light 
chains (highlighting rare reactive plasma cells). Magnification, 400x. (F-I) Osteolytic lesion of 
anaplastic MM with large, immunoblast-like cells with narrow rims of basophilic cytoplasm 
and large central nucleoli, numerous atypical mitoses, and apoptotic bodies. (F) Hematoxylin 
& eosin (H&E) staining, (G) Giemsa staining. Magnification, 400x. (H-I) IHC for (H) MYC 
(only rare positive cells), and (I) Ki-67/MIB-1 (>80% positive cells). Magnification, 100x. (J-
K) Medullary anaplastic MM a predominant population of small to medium sized cells and 
scattered cells with anaplastic morphology. (J) H&E staining, (K) IHC for p53 (homogenous 
and strong positive staining, indicative of p53-mutation). Magnification, 200x. (L-N) MM with 
lymphoplasmacytoid morphology of the BM. (L) H&E staining, (M) Giemsa staining. 
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Magnification, 200x. (N) IHC for cyclin D1 (marked overexpression, indicative of a 
chromosome 11 translocation). Magnification, 400x.  
 
Figure 3. Heterogeneity at the radiological level. Up to 75% of myeloma patients present 
with FLs, and a high number and large size of FLs both are associated with an adverse 
prognosis. FDG-PET (left image) and DW-MRI (right image) of the same patient show 
heterogeneous disease involvement with multiple FLs. Some FLs are well visible in both 
imaging modalities (blue circles), whereas other FLs are much more pronounced in the DW-
MRI (red circles). A possible explanation for these differences is metabolic heterogeneity, in 
that some FLs may express lower levels of hexokinase-2, impairing their uptake of glucose 
[36].  
 
Figure 4. Role of BM microenvironment and host immunity in MM pathogenesis. MM 
cells produce immunosuppressive cytokines including IL-10 and TGF-β (center), directly 
inhibiting T cell responses. In addition, MM cells secrete angiogenic factors VEGF, FGF and 
ANGPT1 that contribute to BM angiogenesis (bottom left). Multiple cell types of the BMME 
produce IL-18, which supports the generation of MDSCs that inhibit CD8+ T cell responses 
(top left). The CXCL12-CXCR4 interaction is important for MM cell retention in the BMME. 
Furthermore, adhesion of MM cells to BMSCs, mediated in part by CD38, activates BMSCs to 
produce IL-6, which in turn stimulates OCs for increased bone resorption (bottom center). OCs 
also directly inhibit the proliferation of CD4+ and CD8+ T cells (top right). Blue arrows indicate 
stimulation, red arrows indicate inhibition. Abbreviations: ANGPT1, angiopoietin-1; BMME, 
bone marrow microenvironment; BMSCs, bone marrow stromal cells; CXCL12, C-X-C 
chemokine ligand type 12; CXCR4, C-X-C chemokine receptor type 4; FGF, fibroblast growth 
factor; IL, interleukin; MDSCs, myeloid-derived suppressor cells; MM cell, multiple myeloma 
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cell; OBs, osteoblasts; OCs, osteoclasts; TGF-β, transforming growth factor-β; VEGF, vascular 
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